Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LATS1 | O95835 | 16/20 | 0.49 |
| ▸ | LATS2 | Q9NRM7 | 8/20 | 0.49 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 2/20 | 0.38 |
| ▸ | GSK3B | P49841 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12620487 | 0.88 | ACP1 (0.47) | LATS1LATS2ALDH1A1SMN1; SMN2 | |
| SCHEMBL801861 | 0.88 | GSK3A (0.50) | NPC1ALDH1A1RAB9ASMN1; SMN2GSK3A | |
| SCHEMBL801656 | 0.83 | GSK3B (0.58) | LATS1LATS2GSK3AGSK3B | |
| SCHEMBL801658 | 0.81 | GRM4 (0.48) | LATS1LATS2ALDH1A1SMN1; SMN2GSK3A | |
| SCHEMBL12620467 | 0.75 | ACP1 (0.60) | ALDH1A1GSK3AGSK3B | |
| SCHEMBL802833 | 0.73 | ACP1 (0.47) | NPC1ALDH1A1RAB9ASMN1; SMN2GSK3A | |
| SCHEMBL12619895 | 0.71 | GSK3B (0.54) | LATS1LATS2GSK3AGSK3B | |
| SCHEMBL801850 | 0.71 | CYP1A2 (0.55) | LATS1LATS2ALDH1A1GSK3AGSK3B | |
| SCHEMBL801844 | 0.70 | GSK3A (0.48) | NPC1ALDH1A1RAB9ASMN1; SMN2GSK3A | |
| SCHEMBL802026 | 0.69 | GSK3B (0.76) | GSK3AGSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8633210-B2 | Triazole compounds useful as protein kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-01-21 | — | — | US | disclosed |
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120071657-A1 | TRIAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS | GSK3B, GSK3A, CDK19 | LATS1 1086/4885LATS2 1373/4885NPC1 2844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.